Literature DB >> 34965972

Distinct Factors Drive the Spatiotemporal Progression of Tau Pathology in Older Adults.

Jenna N Adams1, Theresa M Harrison2, Anne Maass2,3, Suzanne L Baker4, William J Jagust2,4.   

Abstract

Mechanisms underlying the initial accumulation of tau pathology across the human brain are largely unknown. We examined whether baseline factors including age, amyloid-β (Aβ), and neural activity predicted longitudinal tau accumulation in temporal lobe regions that reflect distinct stages of tau pathogenesis. Seventy cognitively normal human older adults (77 ± 6 years, 59% female) received two or more 18F-flortaucipir (FTP) and 11C-Pittsburgh Compound B (PiB) PET scans (mean follow-up, 2.5 ± 1.1 years) to quantify tau and (Aβ). Linear mixed-effects models were used to calculate the slopes of FTP change in entorhinal cortex (EC), parahippocampal cortex (PHC), and inferior temporal gyrus (IT), and slopes of global PiB change. Thirty-seven participants underwent functional MRI to measure baseline activation. Older age predicted EC tau accumulation, and baseline EC tau levels predicted subsequent tau accumulation in EC and PHC. In IT, however, baseline EC tau interacted with Aβ to predict IT tau accumulation. Higher baseline local activation predicted tau accumulation within EC and PHC, and higher baseline hippocampal activation predicted EC tau accumulation. Our findings indicate that factors predicting tau accumulation vary as tau progresses through the temporal lobe. Older age is associated with initial tau accumulation in EC, while baseline EC tau and neural activity drive tau accumulation within medial temporal lobe. Aβ subsequently facilitates tau spread from medial to lateral temporal lobe. Our findings elucidate potential drivers of tau accumulation and spread in aging, which are critical for understanding Alzheimer's disease pathogenesis.SIGNIFICANCE STATEMENT To further understand the mechanisms leading to tau pathogenesis and spread, we tested whether baseline factors such as age, amyloid-β pathology, and activation predicted longitudinal tau accumulation in cognitively normal older adults. We found that distinct mechanisms contribute to tau accumulation as tau progresses across the temporal lobe, with initial tau accumulation in entorhinal cortex driven by age and subsequent spread driven by neural activity and amyloid-β. We demonstrate that higher baseline activation predicts increased longitudinal tau accumulation, providing novel evidence that activation-dependent tau production may occur in the human brain. Our findings support major hypotheses generated from preclinical research, and have important translational implications, suggesting that the reduction of hyperactivation may help prevent the development of tau pathology.
Copyright © 2022 the authors.

Entities:  

Keywords:  Alzheimer's disease; PET; aging; amyloid-β; fMRI; tau

Mesh:

Substances:

Year:  2021        PMID: 34965972      PMCID: PMC8883857          DOI: 10.1523/JNEUROSCI.1601-21.2021

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.709


  44 in total

1.  Graphical analysis of PET data applied to reversible and irreversible tracers.

Authors:  J Logan
Journal:  Nucl Med Biol       Date:  2000-10       Impact factor: 2.408

Review 2.  Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

3.  Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study.

Authors:  Hanna Cho; Jae Yong Choi; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Clifford R Jack; Chul Hyoung Lyoo
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

Review 4.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

5.  Age-related functional changes in domain-specific medial temporal lobe pathways.

Authors:  David Berron; Katja Neumann; Anne Maass; Hartmut Schütze; Klaus Fliessbach; Verena Kiven; Frank Jessen; Magdalena Sauvage; Dharshan Kumaran; Emrah Düzel
Journal:  Neurobiol Aging       Date:  2018-01-31       Impact factor: 4.673

6.  Reduced Repetition Suppression in Aging is Driven by Tau-Related Hyperactivity in Medial Temporal Lobe.

Authors:  Jenna N Adams; Anne Maass; David Berron; Theresa M Harrison; Suzanne L Baker; Wesley P Thomas; Morgan Stanfill; William J Jagust
Journal:  J Neurosci       Date:  2021-03-17       Impact factor: 6.167

7.  Frequency of stages of Alzheimer-related lesions in different age categories.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

8.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Authors:  Sylvia Villeneuve; Gil D Rabinovici; Brendan I Cohn-Sheehy; Cindee Madison; Nagehan Ayakta; Pia M Ghosh; Renaud La Joie; Samia Kate Arthur-Bentil; Jacob W Vogel; Shawn M Marks; Manja Lehmann; Howard J Rosen; Bruce Reed; John Olichney; Adam L Boxer; Bruce L Miller; Ewa Borys; Lee-Way Jin; Eric J Huang; Lea T Grinberg; Charles DeCarli; William W Seeley; William Jagust
Journal:  Brain       Date:  2015-05-06       Impact factor: 13.501

9.  Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data.

Authors:  Suzanne L Baker; Anne Maass; William J Jagust
Journal:  Data Brief       Date:  2017-10-16

10.  A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.

Authors:  Michael J Pontecorvo; Michael D Devous; Ian Kennedy; Michael Navitsky; Ming Lu; Nicholas Galante; Stephen Salloway; P Murali Doraiswamy; Sudeepti Southekal; Anupa K Arora; Anne McGeehan; Nathaniel C Lim; Hui Xiong; Stephen P Truocchio; Abhinay D Joshi; Sergey Shcherbinin; Brian Teske; Adam S Fleisher; Mark A Mintun
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.